-

05:39:57 PM

UCBJY Stock News

UCBJY - UCB SA

03/18/23 2:10 PM

OTC : UCBJY

clinical trial

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

UCB, a global biopharmaceutical company, today announced detailed positive results from two Phase 3 studies evaluating the efficacy and safety of bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa. 1 Data from the two studies showed that bimekizumab achieved...

RHEA-AI

very positive

03/16/23 7:00 AM

OTC : UCBJY

conferences

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

UCB, a global biopharmaceutical company, today announced that it

RHEA-AI

negative

01/18/23 7:00 AM

OTC : UCBJY

clinical trial

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB, a global biopharmaceutical company, today announced that

RHEA-AI

neutral

01/06/23 7:00 AM

OTC : UCBJY

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetycholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive Rozanolixizumab

RHEA-AI

neutral

12/09/22 7:00 AM

OTC : UCBJY

clinical trial

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Top-line results show that the two Phase 3 studies, BE HEARD I and BE HEARD II, met their primary and key secondary endpoints with statistical significance and consistent clinical relevance First Phase 3 evidence to suggest that targeting IL-17F in addition to IL-17A may be a promising treatment

RHEA-AI

positive

12/07/22 7:00 AM

OTC : UCBJY

clinical trial

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

UCB, a global biopharmaceutical company,

RHEA-AI

neutral

12/01/22 7:00 AM

OTC : UCBJY

conferences

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

21 scientific presentations, including 7 late breakers, showcase the breadth of UCB's portfolio, reinforcing commitment to improving the lives of people living with epilepsy New data include insights into the efficacy and safety profile of BRIVIACT ® (brivaracetam) CV, FINTEPLA ® (fenfluramine)

RHEA-AI

neutral

11/23/22 7:00 AM

OTC : UCBJY

Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Peer-reviewed results from the Phase 3 open-label extension study of FINTEPLA ® in LGS provide significant reduction in the frequency of multiple seizure types associated with a drop or fall for 15 months, including tonic and generalized tonic-clonic seizures 1 The cardiovascular safety in this

RHEA-AI

neutral

11/14/22 7:00 AM

OTC : UCBJY

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine receptor antibody positive (AChR-Ab+) Acceptance by U.S. Food and Drug Administration (FDA) follows the recent European Medicines Agency (EMA)

RHEA-AI

neutral

11/10/22 7:00 AM

OTC : UCBJY

clinical trial

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

New late-breaking 52-week data from Phase 3 bimekizumab investigational studies in psoriatic arthritis and across the spectrum of axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing spondylitis, presented at ACR Convergence 2022 In BE OPTIMAL, clinical joint

RHEA-AI

positive